Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis

European Urology

Volumn 72, Issue 5, 2017, Pages 660-664

  Bhindi, Bimal ^a   Frank, Igor ^a   Mason, Ross J ^a   Tarrell, Robert F ^a   Thapa, Prabin ^a   Cheville, John C ^a   Costello, Brian A ^a   Pagliaro, Lance C ^a   Karnes, R Jeffrey ^a   Thompson, R Houston ^a   Tollefson, Matthew K ^a   Boorjian, Stephen A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antineoplastic agents; Cisplatin; Cystectomy; Neoadjuvant therapy; Urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CYSTECTOMY; HUMAN; MAJOR CLINICAL STUDY; NEOADJUVANT CHEMOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85019858599     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.05.016     Document Type: Article

References (12)

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48 (2005), 202–205.
2. International Collaboration of Trialists, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-7 http://dx.doi.org/10.1200/JCO.2010.32.3139.
3. Lavery, H.J., Stensland, K.D., Niegisch, G., Albers, P., Droller, M.J., Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. J Urol 191 (2014), 898–906.
4. Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Vavassori, I., Barni, S., Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65 (2014), 350–357.
5. Zargar, H., Espiritu, P.N., Fairey, A.S., et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 67 (2015), 241–249.
6. Faltas, B.M., Prandi, D., Tagawa, S.T., et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet 48 (2016), 1490–1499.
7. Sonpavde, G., Goldman, B.H., Speights, V.O., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115 (2009), 4104–4109.
8. Chappidi, M.R., Kates, M., Brant, A., et al. Assessing cancer progression and stable disease after neoadjuvant chemotherapy for organ-confined muscle-invasive bladder cancer. Urology 102 (2017), 148–158.
9. Rosenblatt, R., Sherif, A., Rintala, E., et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61 (2012), 1229–1238.
10. Seisen, T., Sonpavde, G., Kachroo, N., et al. Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder. Eur Urol Suppl, 16, 2017, e291.
11. Plimack, E.R., Dunbrack, R.L., Brennan, T.A., et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 68 (2015), 959–967.
12. Liu, D., Plimack, E.R., Hoffman-Censits, J., et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2 (2016), 1094–1096.